Relapsed hodgkin lymphoma in older patients: A comprehensive analysis from the german hodgkin study group

Journal of Clinical Oncology

Volumn 31, Issue 35, 2013, Pages 4431-4437

  Böll, Boris ^a,b   Goergen, Helen ^b   Arndt, Nils ^c   Meissner, Julia ^d   Krause, Stefan W ^e   Schnell, Roland ^f   Von Tresckow, Bastian ^a,b   Eichenauer, Dennis A ^a,b   Sasse, Stephanie ^a,b   Fuchs, Michael ^a,b   Behringer, Karolin ^a,b   Klimm, Beate C ^a,b   Naumann, Ralph ^c   Diehl, Volker ^b   Engert, Andreas ^a,b   Borchmann, Peter ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b German Hodgkin Study Group   (Germany)

^c Stiftungsklinikum Mittelrhein   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f Pioh Medical Oncology and Hematology ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARMUSTINE; CISPLATIN; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; SALVAGE THERAPY; SURVIVAL RATE; CAUSE OF DEATH; CHEMORADIOTHERAPY; COHORT ANALYSIS; DISEASE COURSE; GERMANY; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; STATISTICS; SURVIVOR; PROCEDURES; STATISTICS AND NUMERICAL DATA;

AGED; CAUSE OF DEATH; CHEMORADIOTHERAPY; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GERMANY; HODGKIN DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; SALVAGE THERAPY; SURVIVAL RATE; SURVIVORS;

EID: 84894356294     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.8246     Document Type: Article

References (30)

1. Sjöberg J, Halthur C, Kristinsson SY, et al: Progress in Hodgkin lymphoma: A population-based study on patients diagnosed in Sweden from 1973-2009. Blood 119:990-996, 2012
2. Evens AM, Helenowski I, Ramsdale E, et al: A retrospective multicenter analysis of elderly Hodgkin lymphoma: Outcomes and prognostic factors in the modern era. Blood 119:692-695, 2012
3. Thieblemont C, Coiffier B: Lymphoma in older patients. J Clin Oncol 25:1916-1923, 2007 (Pubitemid 46854426)
4. Halbsguth TV, Böll B, Borchmann P, et al: The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma. Curr Hematol Malig Rep 6:164-171, 2011
5. Borchmann P, Eichenauer DA, Engert A: State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol 9:450-459, 2012
6. Landgren O, Algernon C, Axdorph U, et al: Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 88:438-444, 2003 (Pubitemid 36547130)
7. Björkholm M, Svedmyr E, Sjöberg J: How we treat elderly patients with Hodgkin lymphoma. Curr Opin Oncol 23:421-428, 2011
8. Böll B, Bredenfeld H, Görgen H, et al: Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 118:6292-6298, 2011
9. Proctor SJ, Wilkinson J, Jones G, et al: Prospective evaluation of treatment outcome in 175 patients with Hodgkin Lymphoma (HL) aged sixty years or over: The SHIELD study. Blood 119:6005-6015, 2012
10. Ballova V, Rüffer JU, Haverkamp H, et al: A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9 elderly). Ann Oncol 16:124-131, 2005 (Pubitemid 40124489)
11. Engert A, Ballova V, Haverkamp H, et al: Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 23: 5052-5060, 2005 (Pubitemid 46224012)
12. Schmitz N, Pfistner B, Sextro M, et al: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 359:2065-2071, 2002 (Pubitemid 34680969)
13. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 341:1051-1054, 1993 (Pubitemid 23114397)
14. Kuruvilla J, Keating A, Crump M: How I treat relapsed and refractory Hodgkin lymphoma. Blood 117:4208-4217, 2011
15. Josting A, Müller H, Borchmann P, et al: Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 28:5074-5080, 2010
16. Borchmann P, Haverkamp H, Diehl V, et al: Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: Final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 29:4234-4242, 2011
17. Eich HT, Diehl V, Görgen H, et al: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28: 4199-4206, 2010
18. Engert A, Schiller P, Josting A, et al: Involvedfield radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with earlystage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601-3608, 2003 (Pubitemid 46594052)
19. Engert A, Franklin J, Eich HT, et al: Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol 25:3495-3502, 2007 (Pubitemid 47310889)
20. Engert A, Diehl V, Franklin J, et al: Escalateddose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548-4554, 2009
21. Engert A, Plütschow A, Eich HT, et al: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010
22. Halbsguth TV, Nogová L, Mueller H, et al: Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: A report from the German Hodgkin Study Group (GHSG). Blood 116:2026-2032, 2010
23. Josting A, Franklin J, May M, et al: New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 20:221-230, 2002 (Pubitemid 34032615)
24. Extermann M, Hurria A: Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25:1824-1831, 2007 (Pubitemid 46860271)
25. Sorror ML, Maris MB, Storb R, et al: Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106:2912-2919, 2005 (Pubitemid 41510773)
26. Krug U, Röllig C, Koschmieder A, et al: Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: A web-based application for prediction of outcomes. Lancet 376:2000-2008, 2010
27. Puig N, Pintilie M, Seshadri T, et al: High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma. Bone Marrow Transplant 46: 1339-1344, 2011
28. Gopal AK, Ramchandren R, O'Connor OA, et al: Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 120:560-568, 2012
29. Younes A, Gopal AK, Smith SE, et al: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30:2183-2189, 2012
30. Chen R, Palmer JM, Thomas SH, et al: Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 119: 6379-6381, 2012